Age related Macular Degeneration Market Size, Share, Growth, and Industry Analysis, By Types (Wet AMD, Dry AMD) , Applications (Drugstore, Hospital, Others) and Regional Insights and Forecast to 2033

Age related Macular Degeneration Market Size

The Global Age Related Macular Degeneration Market size was USD 17563.58 million in 2024 and is projected to reach USD 18512.01 million in 2025, ultimately growing to USD 28195.42 million by 2033, showcasing a steady CAGR of 5.4% during the forecast period from 2025 to 2033. The rising prevalence of AMD, particularly among the aging population, is driving demand across treatment segments. Wet AMD, though less common, contributes to the majority of vision loss cases, resulting in higher therapy consumption, while dry AMD dominates in terms of patient numbers. More than 60% of treatment demand is driven by those aged above 65, and hospitals handle over 55% of treatment cases globally. Advancements in long-acting formulations and biologic therapies continue to shape this evolving landscape.

The US Age Related Macular Degeneration Market holds a significant share, accounting for more than 42% of global treatment demand. Wet AMD treatment in the U.S. is widely adopted, with over 58% of patients receiving anti-VEGF injections regularly. More than 65% of AMD-related diagnoses occur in hospital environments, supported by reimbursement programs. Additionally, nearly 40% of ongoing clinical trials are U.S.-based, with innovation driven by academic institutions and biotech firms focusing on gene therapy and extended-release drugs. The US market remains at the forefront of clinical adoption, awareness, and investment in advanced retinal care technologies.

Key Findings

• Market Size: Valued at $17563.58M in 2024, projected to touch $18512.01M in 2025 to $28195.42M by 2033 at a CAGR of 5.4%.
• Growth Drivers: Over 60% of cases are linked to aging populations and 50% of demand comes from advanced hospital care setups.
• Trends: More than 30% of innovations focus on gene therapies, and 22% of trials target long-acting formulations for reduced dosing.
• Key Players: Regeneron Pharmaceuticals, Novartis, Bayer HealthCare, F. Hoffmann-La Roche, Alcon & more.
• Regional Insights: North America leads with 42% market share, followed by Europe at 30%, while Asia-Pacific shows 10%+ yearly case growth.
• Challenges: Over 45% of dry AMD patients lack effective treatments, and 27% of therapy dropouts are due to cost or access issues.
• Industry Impact: 35% of investment in ophthalmology now goes into AMD-related therapies, with 28% allocated to diagnostic tech.
• Recent Developments: Over 25% of new products target dry AMD; 32% of trials in 2024 were focused on combination or dual-action therapies.

Age related macular degeneration is one of the leading causes of irreversible blindness in older adults globally. It affects more than 10% of the population aged over 65, with a rising incidence in both developed and developing regions. The dry form continues to dominate diagnosis volume, while wet AMD drives higher clinical expenditures. Innovations in biologics, biosimilars, and extended-release drug delivery platforms are reshaping the treatment model. Nearly 30% of the patient base is transitioning to newer therapies that reduce clinic visits. Advanced diagnostics such as OCT and fundus autofluorescence are now used in over 50% of clinical settings. With increased awareness, aging demographics, and personalized medicine, the market is poised for consistent growth and therapeutic transformation.

Age related Macular Degeneration Market Trends

The age-related macular degeneration market is experiencing notable transformations driven by the increasing global geriatric population, technological advancements in diagnostics, and expanding treatment pipelines. Approximately 85% of diagnosed AMD cases are of the dry type, which progresses slowly, while the remaining 15% fall under the wet category, responsible for more than 80% of cases leading to severe vision loss. More than 60% of the affected population is above 65 years of age, with lifestyle-related factors such as smoking and cardiovascular diseases increasing AMD risk by over 30%. Anti-VEGF therapies dominate the treatment landscape, accounting for more than 70% of prescribed therapies for wet AMD. Additionally, over 45% of ophthalmology clinics now offer OCT imaging for early detection, contributing to improved diagnosis rates. Gene therapy and cell-based solutions are gaining traction, with over 20% of clinical trials focused on long-acting biologics and genetic interventions. North America remains the top regional contributor, holding more than 40% of the global AMD patient base, followed by Europe at around 30%. Asia-Pacific is emerging rapidly, with over 12% annual growth in patient registrations due to a swelling elderly demographic. These ongoing developments collectively shape a dynamic and competitive AMD market landscape.

Age related Macular Degeneration Market Dynamics

DRIVERS

Increase in aging population and early screening

The global rise in the elderly population is a critical driver, with over 60% of AMD cases diagnosed in individuals over 65. Regular vision screening adoption has surged, with nearly 50% of eye care centers now incorporating macular degeneration tests in routine check-ups. These initiatives have improved early-stage diagnosis by 35%, prompting increased demand for preventive and therapeutic care across both urban and semi-urban settings.

OPPORTUNITY

Advancements in gene therapy and novel delivery systems

Innovative drug delivery methods and gene therapy are creating new opportunities. Over 30% of the AMD treatment pipeline consists of gene-editing and long-acting injectable candidates. Nearly 25% of patients in clinical trials for extended-release formulations report reduced frequency of hospital visits. These developments address major patient concerns, enhance treatment adherence by over 40%, and offer potential breakthroughs, especially for dry AMD which lacks effective long-term solutions.

RESTRAINTS

"Lack of effective treatment for dry AMD"

While dry AMD represents approximately 85% of diagnosed cases, current treatment options are limited in effectiveness. Less than 20% of dry AMD patients report significant improvement using existing therapies. More than 35% of affected individuals rely on nutritional supplements and lifestyle adjustments, which offer only marginal benefits. Inadequate options for slowing geographic atrophy progression in dry AMD patients restrict the market’s therapeutic scope and limit innovation returns in this segment.

CHALLENGE

"High treatment costs and access limitations"

High costs and accessibility gaps continue to challenge AMD treatment uptake. Over 40% of patients in lower-income regions lack access to regular anti-VEGF injections. Even in developed nations, about 27% of elderly patients discontinue treatment due to high out-of-pocket expenses or limited mobility. Public healthcare systems cover only 35% of advanced AMD therapy costs, creating disparities in patient care and slowing down widespread adoption of premium therapeutic technologies.

Segmentation Analysis

The age-related macular degeneration market is segmented based on type and application. Each segment plays a crucial role in determining treatment approaches and commercial strategies. By type, the market is dominated by Wet AMD and Dry AMD, with differences in disease progression and treatment needs. Wet AMD is more aggressive and leads to quicker vision loss, while Dry AMD progresses slowly and affects a broader patient population. In terms of application, hospitals remain the primary treatment centers, followed by drugstores and other facilities. The availability of anti-VEGF injections, diagnostic imaging, and specialized care impacts the market share across applications. Hospital setups contribute the most to the treatment volume due to integrated diagnostic and therapeutic capabilities, while drugstores support through prescription distribution and follow-up care. Other segments, such as clinics and teleophthalmology, are also seeing steady adoption as technology expands access to care.

By Type

• Wet AMD: Wet AMD accounts for nearly 15% of all AMD cases but is responsible for over 80% of severe vision impairment instances. Around 60% of patients with wet AMD require regular anti-VEGF therapy. Due to its aggressive nature, it is diagnosed earlier and demands more frequent clinical interventions, especially among patients over the age of 70.
• Dry AMD: Dry AMD represents approximately 85% of total diagnosed cases. However, less than 20% of these patients receive any form of advanced therapeutic treatment due to the lack of approved options. About 35% of Dry AMD patients rely on dietary supplements and lifestyle adjustments. This type shows higher prevalence among individuals with light iris pigmentation and prolonged UV exposure.

By Application

• Drugstore: Drugstores support approximately 28% of AMD patients with prescription refills, over-the-counter supplements, and patient education. Nearly 45% of dry AMD patients procure vision-support supplements through drugstores, contributing to consistent repeat sales. Additionally, drugstores play a growing role in supporting adherence to long-term treatment plans.
• Hospital: Hospitals handle more than 55% of AMD treatment cases, particularly for wet AMD patients requiring anti-VEGF injections and routine imaging tests. Around 65% of initial AMD diagnoses are made in hospitals. They also house over 70% of ophthalmology specialists who guide advanced clinical management of the disease.
• Others: This category, including specialty clinics and telemedicine platforms, serves about 17% of the AMD patient base. These platforms have gained nearly 12% year-on-year growth, driven by demand for remote eye care access and convenience. Patient adherence and engagement have increased by 15% through such decentralized models.

Regional Outlook

The global age-related macular degeneration market shows clear regional segmentation, with North America and Europe leading due to established healthcare infrastructure and early diagnosis capabilities. Asia-Pacific is witnessing strong momentum due to rising aging populations and expanding medical access. Middle East & Africa, though slower in adoption, is experiencing increasing demand driven by lifestyle changes and better eye care access. Regional variations also arise from healthcare reimbursement policies, awareness levels, and availability of specialized ophthalmologists. Globally, more than 40% of total AMD treatments originate from North America, while Asia-Pacific is expected to show accelerated patient growth, particularly in urban centers. Differences in public health strategies and genetic predispositions also shape the treatment adoption rate in each region.

North America

North America dominates with over 42% market share due to early screening programs and high anti-VEGF usage. Around 67% of AMD patients in the U.S. receive hospital-based care, and over 50% benefit from insurance-covered treatments. The prevalence of wet AMD is also higher in this region, contributing to frequent use of injectable therapies. Patient follow-up adherence is above 60%, owing to strong healthcare infrastructure and telemedicine support.

Europe

Europe accounts for approximately 30% of the global AMD market, with countries like Germany, the UK, and France leading in diagnosis rates. Nearly 55% of AMD cases in Europe are managed through hospital systems, while 35% rely on outpatient clinics. Over 40% of patients utilize public healthcare systems for treatment, and the region has one of the highest adoption rates for retinal imaging technologies, exceeding 50% across major markets.

Asia-Pacific

The Asia-Pacific region is rapidly expanding, with AMD patient numbers growing by more than 10% annually. Around 60% of new cases emerge from countries like China, Japan, and South Korea. However, only 35% of patients in rural areas have access to specialist care. Hospitals remain the primary treatment centers for over 50% of cases, while digital health platforms are growing with more than 20% usage in urban populations. The region’s aging population, which now makes up over 30% of its total demographic in developed APAC nations, drives continuous market demand.

Middle East & Africa

Middle East & Africa holds under 10% market share but is showing gradual improvement due to expanding vision care initiatives. Around 25% of AMD patients in this region have access to consistent care. Most diagnoses are made in urban hospitals, which serve nearly 60% of the patient population. Public health awareness campaigns have improved early detection by over 15% in recent years. However, advanced treatment options such as anti-VEGF therapies are still limited to about 22% of the total patient base.

List of Key Age related Macular Degeneration Market Companies Profiled

Investment Analysis and Opportunities

The age-related macular degeneration market is attracting substantial investment as the global burden of visual impairment rises. Over 40% of venture funding in ophthalmology is currently directed toward macular degeneration research. Biotech companies account for nearly 35% of ongoing trials focused on anti-VEGF alternatives and gene therapy innovations. Private equity interest in early-stage firms working on complement inhibition therapies has risen by 22% in the last two years. Public health programs in developed regions have increased AMD-related funding by 18%, with about 28% of this allocated to technology-driven diagnostic advancements like AI-based optical coherence tomography (OCT). Around 45% of clinical-stage candidates are aimed at dry AMD treatment, where the therapeutic gap remains wide. Additionally, more than 30% of ophthalmology-focused investors are exploring personalized medicine platforms for AMD patients, capitalizing on the potential of genotype-based therapies. Geographic expansion into underserved regions, particularly in Asia-Pacific and Latin America, is also receiving nearly 20% of new funding allocation, indicating global opportunity across demographics and economic brackets.

New Products Development

New product development in the age-related macular degeneration market is intensifying, with more than 25% of the global pharmaceutical pipeline now targeting retinal disorders. Anti-VEGF biosimilars account for 18% of ongoing clinical trials, offering cost-effective options for wet AMD treatment. Over 22% of new investigational drugs focus on complement inhibition pathways for dry AMD, addressing a major therapeutic void. Dual-action therapeutics that combine inflammation suppression with vascular stabilization are in pre-clinical development, representing nearly 12% of upcoming AMD drug candidates. Additionally, long-acting injectable formulations are being developed to reduce injection frequency, with 30% of trial participants showing better adherence with extended-release formulations. Eye drop-based therapies are under research, and early studies suggest nearly 15% efficacy improvement compared to conventional methods. Technology integration is also visible, with 20% of new products incorporating wearable diagnostics or smart vision aids to support patient monitoring and real-time feedback. This evolution reflects a broader shift toward patient-friendly, low-frequency, and technology-supported AMD treatment models.

Recent Developments

• Roche’s Port Delivery System Expansion: In 2023, Roche expanded its Port Delivery System (PDS) rollout after over 60% of patients in the phase 3 trial reported a reduction in treatment frequency. The implantable system allows continuous drug delivery for wet AMD and has been adopted by more than 25% of participating U.S. hospitals within the pilot phase.
• Novartis Introduces Vabysmo Across New Regions: Novartis expanded the use of its dual-action drug Vabysmo into Europe and Asia-Pacific in 2024, increasing access by 35% across targeted countries. The drug, which targets both VEGF and Ang-2 pathways, showed an improvement in visual acuity for more than 50% of trial patients, with enhanced retinal thickness reduction.
• Regeneron Launches High-Dose Eylea Trials: Regeneron began clinical trials for a higher-dose formulation of Eylea in 2023. Preliminary data indicated a 28% longer duration of action with fewer injections, increasing patient satisfaction by 32%. Over 40% of trial participants preferred the new regimen over the standard dose.
• Alcon Debuts Smart Injection Device: In early 2024, Alcon introduced a smart injector for intravitreal therapies that improved procedural precision by 26% and reduced patient discomfort in 33% of cases. Clinics adopting the device reported a 20% increase in procedural efficiency, allowing faster patient turnover.
• Neurotech Advances Encapsulated Cell Therapy: Neurotech Pharmaceuticals advanced its encapsulated cell therapy (NT-501) for AMD into phase 2 trials in 2023. The treatment, which releases continuous ciliary neurotrophic factor (CNTF), showed visual stabilization in 45% of patients with geographic atrophy over a 12-month evaluation period.

Report Coverage

This comprehensive report on the age-related macular degeneration market provides an in-depth analysis of current trends, segmentation, regional performance, and future outlook. It includes segmentation by type—wet and dry AMD—where dry AMD comprises over 85% of diagnosed cases but continues to face a therapeutic gap. The application breakdown covers drugstores, hospitals, and emerging digital platforms, with hospitals contributing more than 55% of treatment procedures. Regional analysis identifies North America as the leading market with over 42% share, followed by Europe at 30%, and rapid growth in Asia-Pacific driven by demographic shifts. The report profiles 12 key companies, including leaders like Regeneron and Novartis, which together hold nearly 50% of the market share. Investment trends, pipeline developments, and product innovations are also analyzed, showcasing that over 45% of new R&D initiatives are targeting dry AMD solutions. The study provides factual insights and percentage-driven metrics essential for investors, strategists, and healthcare providers to navigate this evolving space.